

**UNIVERSITI TEKNOLOGI MARA**

**CLINICAL PROFILE AND RESPONSE TO  
TREATMENT WITH PEGYLATED INTERFERON  
PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C  
PATIENTS IN SELAYANG HOSPITAL**

**ADLIN NADIA ZAKARIA**

Dissertation submitted in partial fulfilment of the requirements  
for the degree of  
**Master of Clinical Pharmacy**

**Faculty of Pharmacy**

**January 2015**

## AUTHOR'S DECLARATION

I declare that the work in this dissertation was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the result of my own work, unless otherwise indicated or acknowledged as referenced work. This writing has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I hereby acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name : Adlin Nadia Zakaria  
Student ID : 2013270704  
Department : Clinical Pharmacy  
Faculty : Pharmacy  
Dissertation : Clinical Profile And Response To Treatment  
With Pegylated Interferon Plus Ribavirin For  
Chronic Hepatitis C Patients In Selayang  
Hospital  
Signature : .....  
Date : January 2015

## ABSTRACT

AIM: To identify the clinical profile of chronic hepatitis C patients treated with pegylated interferon plus ribavirin in Selayang Hospital from year 2004-2012. It is also to determine factors associated with treatment response. METHODS: 273 patients treated with pegylated interferon plus ribavirin for CHC were identified. Patient's data were accessed retrospectively through electronic medical records. Descriptive data were analysed using frequency and percentage. Simple logistic regression was used for univariate analyses. Factors with significant  $p$  value were analysed using multiple logistic regression. RESULTS: The mean age of patients treated was 44.16 ( $\pm$  10.51). More men were treated compared to women (76.6% vs. 23.4%). Major ethnicity distribution was Chinese 48.7%, and Malays 38.5%. Majority of patients have very high baseline viral load (median  $>800,000$  iu/ml). Genotype 3a predominates (58.2%), while genotype 1 come a close second (1a= 20.1% and 1b=12.5%). Fifty nine percent of all treated population achieved SVR. DISCUSSIONS: Twelve factors were identified as possible SVR predictors; age ( $p=0.002$ ), pegylated interferon dose disruption ( $p=0.012$ ), ribavirin dose disruption ( $p=0.223$ ), genotype 3a ( $p=0.239$ ), pre-existing diabetes mellitus type 2 ( $p=0.042$ ), pre-existing kidney related disease ( $p=0.042$ ), history of alcohol usage ( $p=0.051$ ), baseline ALT ( $p=0.045$ ), baseline platelet ( $p=0.001$ ), liver biopsy fibrosis score ( $p=0.005$ ), fibroscan reading ( $p=0.149$ ), and RVR ( $p=0.0001$ ). CONCLUSION: The information elucidated from this study could facilitate local physicians decide on the population of CHC patients that should receive treatment.

## ACKNOWLEDGEMENT

First and foremost, I thank Allah for his grace and blessings. My utmost appreciation towards Pharmacy Faculty of UiTM and its academic and non-academic members. I would like to thank Professor Dr Yahaya Hassan and Dr Mahmathi Karupannan, my supervisors, for their time and precious input. I would like to express deepest gratitude to Dr Tan Soek Siam, for her willingness to share her experience, data collection and providing motivation. My sincerest appreciation to Professor Dr Noorizan for her graciousness to provide support when she didn't have the obligation to. My thanks to En. Adam Bujang, Selayang Hospital visiting statistician, for his patience in guiding me through the maze of statistics.

To Selayang Hospital Pharmacy Department, for their graciousness in tolerating my constant presence during data collection, I appreciate the time and space. Last but not least, I would like to thank my family, for their sacrifices and helping hand in time of dire stress.

# TABLE OF CONTENTS

CONFIRMATION BY PANEL OF EXAMINERS .....	ii
AUTHOR'S DECLARATION .....	iii
ABSTRACT .....	iv
ACKNOWLEDGEMENT .....	v
LIST OF TABLES .....	viii
LIST OF FIGURES .....	ix
LIST OF ABBREVIATIONS .....	x
CHAPTER 1: INTRODUCTION .....	1
CHAPTER TWO: LITERATURE REVIEW .....	3
2.1 Definition And Terminology .....	3
2.1.1 Chronic Hepatitis C Infection.....	3
2.1.2 Sustained Virological Response (SVR) .....	4
2.1.3 Rapid Virological Response (RVR) .....	4
2.2 Viral Factors .....	12
2.3 Host Factors .....	12
2.4 External Factors .....	14
2.5 Development Of Treatment Models .....	14
CHAPTER THREE: METHODOLOGY .....	17
3.1 Study Design.....	17
3.2 Study Population.....	17
3.3 Sample Size Determination .....	18
3.4 Data Collection .....	19
3.4.1 Clinical Profile Of Chronic Hepatitis C Patients Treated With Pegylated Interferon Plus Ribavirin .....	19
3.5 Statistical Analysis.....	20
CHAPTER FOUR: RESULTS .....	21